Search Results

You are looking at 81 - 90 of 1,088 items for :

  • "Lung cancer" x
  • Refine by Access: All x
Clear All
Full access

Use of Endobronchial Ultrasound and Endoscopic Ultrasound to Stage the Mediastinum in Early-Stage Lung Cancer

Christopher Gilbert, Lonny Yarmus, and David Feller-Kopman

the mediastinum in early-stage lung cancer. Describe the role of EBUS-TBNA and EUS-FNA in the staging of lung cancer. Lung cancer and its related complications remain the leading cause of cancer-related deaths in the United States. In 2012, an

Full access

Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time?

Charu Aggarwal, Neeta Somaiah, and George R. Simon

L ung cancer is the leading cause of cancer-related mortality in the United States. 1 Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and predominantly encompasses the adenocarcinoma, squamous cell

Full access

Advances in the Treatment of Non-Small Cell Lung Cancer

Leora Horn

“Immunotherapy is one of the exciting areas being explored in lung cancer today, because traditionally it has not worked in lung cancer patients,” according to Leora Horn, MD, MSc, Associate Professor of Medicine, and Clinical Director, Thoracic

Full access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Renato G. Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes

able to: Integrate into professional practice the updates to the NCCN Guidelines for Non–Small Cell Lung Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non–Small Cell Lung Cancer Disclosure of

Full access

Novel Targets for Therapeutic Agents in Small Cell Lung Cancer

Patrick C. Ma and Ravi Salgia

the lung . J Clin Oncol 1995 ; 13 : 1265 – 1279 . 3 Turrisi AT 3rd Kim K Blum R . Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide . N Engl

Full access

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

, 2023; Expiration date: April 10, 2024 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to the NCCN Guidelines for Non–Small Cell Lung Cancer • Describe

Full access

Predictive Molecular Markers: Has the Time Come for Routine Use in Lung Cancer?

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

No benefits or funds were received in support of this study. References 1 Bunn PA Jr Kelly K . New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature

Full access

Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation

Daniel C. McFarland, Devika R. Jutagir, Andrew H. Miller, William Breitbart, Christian Nelson, and Barry Rosenfeld

Background Depression is most prevalent in patients with lung cancers, among all cancer subtypes, despite new and novel lung cancer treatments. 1 , 2 Therefore, depression is one of the most problematic cancer comorbidities for a large number of

Full access

Small Cell Lung Cancer

UCSF Helen Diller Family Comprehensive Cancer Center

Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.

For the most recent version of the guidelines, please visit NCCN.org

Full access

The Impact of Electromagnetic Navigational Bronchoscopy on a Multidisciplinary Thoracic Oncology Program

Craig Brown, Sharon Ben-Or, Paul Walker, and Mark Bowling

Background A multidisciplinary approach to lung cancer has been recommended by treatment guidelines from both the American College of Chest Physicians 1 and NCCN. 2 One part of this approach may involve incorporating new technologies, such